• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Busulfan, fludarabine, and alemtuzumab conditioning and unrelated cord blood transplantation in children with sickle cell disease.

作者信息

Radhakrishnan Kavita, Bhatia Monica, Geyer Mark B, Del Toro Gustavo, Jin Zhezhen, Baker Courtney, Harrison Lauren, Morris Erin, Baxter-Lowe Lee Ann, Cairo Mitchell S

出版信息

Biol Blood Marrow Transplant. 2013 Apr;19(4):676-7. doi: 10.1016/j.bbmt.2013.02.002. Epub 2013 Feb 9.

DOI:10.1016/j.bbmt.2013.02.002
PMID:23403308
Abstract
摘要

相似文献

1
Busulfan, fludarabine, and alemtuzumab conditioning and unrelated cord blood transplantation in children with sickle cell disease.白消安、氟达拉滨和阿仑单抗预处理及无关脐血移植治疗镰状细胞病患儿
Biol Blood Marrow Transplant. 2013 Apr;19(4):676-7. doi: 10.1016/j.bbmt.2013.02.002. Epub 2013 Feb 9.
2
Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.马利兰、氟达拉滨和阿仑单抗作为降低毒性方案用于治疗儿童恶性和非恶性疾病可改善植入和移植物抗宿主病，而不延迟免疫重建。
Biol Blood Marrow Transplant. 2012 Nov;18(11):1656-63. doi: 10.1016/j.bbmt.2012.05.006. Epub 2012 May 15.
3
Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection.无关供者造血干细胞移植治疗非恶性遗传性疾病：基于阿仑单抗的方案与临床疾病的治愈相关；阿仑单抗的早期清除可能与移植物排斥有关。
Am J Hematol. 2015 Nov;90(11):1021-6. doi: 10.1002/ajh.24141. Epub 2015 Oct 12.
4
Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cells.采用减强度预处理方案和第三方间充质基质细胞对血红蛋白病患者进行无关供体同种异体造血干细胞移植。
Biol Blood Marrow Transplant. 2014 Apr;20(4):581-6. doi: 10.1016/j.bbmt.2013.12.564. Epub 2013 Dec 24.
5
Fludarabine-based reduced intensity conditioning for stem cell transplantation of Fanconi anemia patients from fully matched related and unrelated donors.基于氟达拉滨的减低强度预处理方案用于范可尼贫血患者接受来自全相合亲属及非亲属供者的干细胞移植。
Biol Blood Marrow Transplant. 2006 Jul;12(7):712-8. doi: 10.1016/j.bbmt.2006.03.002.
6
Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML.采用静脉注射白消安、氟达拉滨和兔抗胸腺细胞球蛋白对患有非恶性疾病和慢性粒细胞白血病的儿童进行减低强度预处理。
Bone Marrow Transplant. 2006 Feb;37(3):263-9. doi: 10.1038/sj.bmt.1705240.
7
Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease Following Reduced-Intensity Conditioning: Results of a Phase I Trial.减低强度预处理后无关供者脐血移植治疗镰状细胞病：一项I期试验的结果
Biol Blood Marrow Transplant. 2017 Sep;23(9):1587-1592. doi: 10.1016/j.bbmt.2017.05.027. Epub 2017 May 31.
8
Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen.采用白消安、噻替哌、氟达拉滨和 ATG 作为清髓性预处理方案，对血液系统恶性肿瘤患者进行非血缘单份脐带血移植。
Bone Marrow Transplant. 2012 Oct;47(10):1287-93. doi: 10.1038/bmt.2012.13. Epub 2012 Feb 13.
9
Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients.氟达拉滨和白消安作为高风险和标准风险白血病患者异基因干细胞移植的清髓性预处理方案。
Bone Marrow Transplant. 2007 Jul;40(2):105-10. doi: 10.1038/sj.bmt.1705685. Epub 2007 Apr 30.
10
Conditioning with purine analogs leads to good engraftment rates of immunodepleted grafts for aplastic anemia.嘌呤类似物预处理可提高免疫抑制后骨髓移植治疗再生障碍性贫血的植入率。
Biol Blood Marrow Transplant. 2013 Apr;19(4):584-8. doi: 10.1016/j.bbmt.2012.12.017. Epub 2012 Dec 25.

引用本文的文献

1
Selecting patients with sickle cell disease for gene addition or gene editing-based therapeutic approaches: Report on behalf of a joint EHA Specialized Working Group and EBMT Hemoglobinopathies Working Party consensus conference.为基于基因添加或基因编辑的治疗方法选择镰状细胞病患者：代表欧洲血液学协会（EHA）专门工作组和欧洲血液与骨髓移植协会（EBMT）血红蛋白病工作组联合共识会议撰写的报告
Hemasphere. 2025 Mar 13;9(3):e70089. doi: 10.1002/hem3.70089. eCollection 2025 Mar.
2
Donor chimerism and immune reconstitution following haploidentical transplantation in sickle cell disease.同种异体移植治疗镰状细胞病中的供者嵌合体和免疫重建。
Front Immunol. 2022 Dec 9;13:1055497. doi: 10.3389/fimmu.2022.1055497. eCollection 2022.
3
Choice of Donor Source and Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Sickle Cell Disease.
镰状细胞病造血干细胞移植的供体来源选择和预处理方案
J Clin Med. 2019 Nov 15;8(11):1997. doi: 10.3390/jcm8111997.
4
The Safe Recipient of SSC Transplantation Prepared by Heat Shock With Busulfan Treatment in Mice.热休克预处理联合白消安处理供体小鼠以制备安全的心脏移植供体
Cell Transplant. 2018 Oct;27(10):1451-1458. doi: 10.1177/0963689718794126. Epub 2018 Sep 6.
5
Stem cell transplantation in sickle cell disease: therapeutic potential and challenges faced.镰状细胞病中的干细胞移植：治疗潜力与面临的挑战
Expert Rev Hematol. 2018 Jul;11(7):547-565. doi: 10.1080/17474086.2018.1486703. Epub 2018 Jun 20.
6
Alternative donor hematopoietic stem cell transplantation for sickle cell disease.镰状细胞病的替代供体造血干细胞移植
Blood Adv. 2017 Jun 28;1(16):1215-1223. doi: 10.1182/bloodadvances.2017005462. eCollection 2017 Jul 11.
7
Alternative Donor/Unrelated Donor Transplants for the β-Thalassemia and Sickle Cell Disease.β地中海贫血和镰状细胞病的替代供体/非亲属供体移植
Adv Exp Med Biol. 2017;1013:123-153. doi: 10.1007/978-1-4939-7299-9_5.
8
Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.异基因造血细胞移植中免疫抑制剂的药代动力学、药效学和药物基因组学：第二部分。
Clin Pharmacokinet. 2016 May;55(5):551-93. doi: 10.1007/s40262-015-0340-9.
9
Hematopoietic stem cell transplantation in sickle cell disease: patient selection and special considerations.镰状细胞病中的造血干细胞移植：患者选择及特殊考量
J Blood Med. 2015 Jul 10;6:229-38. doi: 10.2147/JBM.S60515. eCollection 2015.
10
Alternative donor transplant of benign primary hematologic disorders.良性原发性血液系统疾病的替代供体移植
Bone Marrow Transplant. 2015 May;50(5):619-27. doi: 10.1038/bmt.2015.1. Epub 2015 Feb 9.